Seattle Genetics Inc (NASDAQ:SGEN)

55.62
Delayed Data
As of 11:11am ET
 +0.39 / +0.71%
Today’s Change
45.31
Today|||52-Week Range
68.59
+3.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$9.1B

Company Description

Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Contact Information

Seattle Genetics, Inc.
21823 30th Drive SE
Bothell Washington 98021
P:(425) 527-4000
Investor Relations:
(425) 527-4160

Employees

Shareholders

Other institutional63.84%
Mutual fund holders42.60%
Individual stakeholders41.29%

Top Executives

Clay B. SiegallChairman, President & Chief Executive Officer
Todd E. SimpsonCFO & Principal Accounting Officer
Vaughn B. HimesChief Technical Officer
Roger D. DanseyChief Medical Officer
Peter D. SenterVice President-Chemistry